Skip to main content
. 2014 Dec 5;17(1):51–58. doi: 10.1111/jch.12449

Figure 3.

Figure 3

Multivariate analysis of persistence and proportion of days covered. A fixed‐dose combination of amlodipine/valsartan (FDC) and the presence of comorbidities were significantly associated with better persistence and proportion of days covered (PDC) ≥80%. Baseline pill burden and healthcare costs were negative predictors of persistence and PDC ≥80%. ARB+CCB indicates free combinations of angiotensin receptor blockers and calcium channel blockers; HR: hazard ratio; OR: odds ratio.